BioSpace News Archive

Applied Genetic Technologies Corporation today announced that it will report financial results for the quarter ended September 30, 2021 before the market opens on Tuesday, November 9, 2021.

Prometheus Biosciences, Inc. today announced that management will be conducting presentations and fireside chats at the following investor conferences in November and December.n

MiMedx Group, Inc., an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, announced that Timothy R. Wright, Chief Executive Officer, Peter M. Carlson, Chief Financial Officer, and Rohit Kashyap, Ph.D., Chief Commercial Officer, will be participating in the following virtual investor conferences:.

Immutep Limited is pleased to announce the grant of a new patent (number ZL 201610221687) entitled “Use of recombinant LAG-3 or the derivatives thereof for eliciting a monocyte immune response” by the Chinese Patent Office.

Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company ® , today announced the first members of the Akoya Imaging Innovators (I² ) Network , a collaboration of pioneering scientists from world-class research organizations, with ambitions to advance the field of spatial biology.

CASI Pharmaceuticals, Inc. today announced the Company will host a conference call reviewing the third quarter highlights at 8:00 a.m. EDT on Friday , November 12th , 2021.

Transit Scientific announced the FDA clearance of new hydrophilic-coated XO Cross Microcatheters for guidewire support, exchange, and contrast media injection in the peripheral vasculature.

Ionis Pharmaceuticals, Inc. announced today the initiation of CORE, the second Phase 3 clinical study of olezarsen, formerly known as IONIS-APOCIII-LRx.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the third quarter of 2021, on Tuesday, November 9, 2021, before the U.S. financial markets open.

Valted Seq, a biotechnology company focused on the genetic elucidation of neurodegenerative disease pathways to accelerate development of new therapeutics and diagnostics, announced the completion of a seed fundraising round totaling $10.5 million.